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Pulmonary hypertension (PH), regardless of the pathobiol-ogy and site of functional changes, is characterized by an 
asymptomatic or a latent phase followed by a gradual reduction 
in exercise capacity related to decreasing right ventricular (RV) 
contractile reserve.1,2 In addition to right heart and pulmonary 
vascular function, other factors including ventilation/perfu-
sion mismatch, hypoxemia, peripheral oxygen transportation/
utilization, and impaired skeletal muscle function, may signifi-
cantly influence the functional status of patients with PH.3
Guidelines provide a clinical classification system that cat-
egorizes PH into 5 groups with specific pathogenesis, patholo-
gies, and clinical characteristics.1,2 The natural history of the 
disease is determined by the rapidity of increase in resting 
mean pulmonary artery pressure (mPAP) and the ability of the 
RV to compensate and hypertrophy, which differs depending 
on the pathobiology and related diseases.1,2 The definition of 
PH and PH groups is based on clinical assessment and inva-
sive hemodynamics. Precapillary PH (groups 1 and 3–5) is 
characterized as a resting mPAP of ≥25 mm Hg and pulmo-
nary capillary wedge pressure (PCWP) or left ventricular (LV) 
end-diastolic pressure ≤15 mm Hg. Postcapillary PH (group 
2) is associated with an elevated pulmonary venous pres-
sure (>15 mm Hg) related to left heart disease, which may 
involve abnormalities of the LV, mitral valve, or aortic valve.2 
Although the group definitions for PH are helpful, in clinical 
practice, it is not uncommon for patients to have >1 disease 
associated with PH and to have both precapillary and postcap-
illary components, so called multifactorial PH (eg, aortic ste-
nosis, systemic sclerosis, chronic thromboembolic disease) or 
out-of-proportion PH for a given condition (eg, chronic lung 
disease, chronic heart failure).
The concept that symptoms associated with cardiopulmo-
nary diseases would be associated with an abnormal increase 
in mPAP with exercise was demonstrated >60 years ago.4 
Since then, there has been considerable investigation by clini-
cal scientists. The PH guidelines published in 2009 removed 
an exercise mPAP of ≥30 mm Hg as an additional definition of 
PH, not because of the lack of potential value of exercise PAP 
measurements but rather because of inadequate standardiza-
tion of techniques and lack of established ranges of normal 
physiological responses by age and sex. In the 1980’s, age 
was shown to be associated with an increase in exercise mPAP 
per liter increment in cardiac output and in a recent study 
found that ≈50% of healthy people >50 years of age develop 
an mPAP >30 mm Hg during mild exercise.5,6 A substan-
tial amount of enthusiasm remains for considering exercise 
hemodynamics obtained invasively or by noninvasive testing 
to determine pressure-flow and pressure-workload relation-
ships, which can further characterize PH in its asymptomatic 
or latent phase, clarify the contribution of the precapillary and 
postcapillary components, and help determine the prognosis, 
treatment decisions, and response to therapy.
Here, we present the normal pulmonary vascular and physi-
ological responses of the right side of the heart to exercise, the 
responses in each of the major causes of PH, and the potential 
clinical and investigative utility of assessing hemodynamics 
by exercise testing.
Physiology of the Pulmonary Circulation 
at Rest and During Exercise
Exercise stresses the pulmonary circulation through an 
increase in cardiac output (CO) and mean left atrial pressure 
(LAP), each of which results in an increase in mPAP. The 
relationships between mPAP, CO, and LAP are defined by the 
pulmonary vascular resistance (PVR) equation:
PVR mPAP LAP CO    = −( ) / .
 
(1)
The PVR equation rewritten as mPAP=PVR×CO+LAP 
shows how much mPAP increases with CO or LAP at any 
given PVR.1 More than 50 years ago, Paul Wood reported that 
mPAP does not exceed 20 mm Hg at rest as long as PVR, CO, 
and LAP remain within normal limits.4 As discussed earlier, 
PH has been defined by an mPAP at rest ≥25 mm Hg.1,2 An 
mPAP of 21 to 24 mm Hg corresponds to so-called “border-
line PH” of still undetermined clinical relevance. PH can be 
caused by abnormally high PVR, CO, or LAP.1,2
(Circulation. 2013;128:1470-1479.)
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The inherent assumptions of the PVR equation are that 
(mPAP−LAP)/CO relationships are linear and cross the line of 
origin. If these assumptions are correct, PVR should be inde-
pendent of absolute levels of pressure and flow and of mea-
surements at exercise predicted from resting values. However, 
it has been shown that exercise is normally associated with a 
decrease in PVR.5-7 The exercise-induced decrease in PVR is 
attributable to pulmonary vascular recruitment in the setting 
of increased PAP and flow, as well as the distensibility of the 
normal pulmonary resistance vessels. This decrease is greater 
when exercise is performed in the upright position because 
of higher resting PVR resulting from incomplete recruitment 
of pulmonary resistance vessels in the upper portions of the 
lungs at rest. The supine position and mild to moderate exer-
cise allow complete pulmonary vascular recruitment. Most of 
the exercise-induced decrease in PVR is explained by disten-
sion of the pulmonary resistance vessels.5,7
Because resistance vessels are distensible, multipoint 
mPAP/CO relationships normally present with a slight cur-
vilinearity (Figure 1).7,8 Adjustment of these pressure-flow 
curves with a mathematical model of the pulmonary circula-
tion allows for a recalculation of a distensibility coefficient, α, 
which can be introduced into a refined PVR equation for an 











where R0 is PVR and Q is pulmonary blood flow.8 The dis-
tensibility coefficient α defines how much resistance vessel 
diameters increase as a percent of baseline per mmHg distend-
ing pressure. The normal value of α is 2% per mmHg. This 
value has been established in pulmonary vessels mounted in 
vitro and is remarkably constant from one species to another.8 
The coefficient α is higher in pre-menopausal women as com-
pared to men9 and decreases with age.8,9 A seemingly-modest 
2% distensibility of pulmonary resistive vessels is actually a 
major cause of the limitation of increase in mPAP and decrease 
in PVR normally observed with exercise (Figure 2).7 The sen-
sitivity of α to early pulmonary vascular disease is currently 
under investigation.
In patients with cardiac or pulmonary diseases, PVR has 
been reported to decrease during exercise in some studies, 
but other studies have reported unchanged or even increased 
PVR during exercise, depending on body position and work-
load.5,7 In general, an exercise-induced increase in PVR may 
be observed in heart failure and pulmonary vascular disease 
when resting measurements are performed in the supine posi-
tion and when patients perform maximum tolerated exercise.5,7 
In most situations, the number of recovered mPAP/CO coor-
dinates remains limited when workload is moderate. In these 
circumstances, multipoint mPAP/CO plots are best described 
by a linear approximation. Such a dynamic PVR still offers a 
more robust definition of the functional state of the pulmonary 
circulation than a single-point PVR.5,7
Invasive as well as non-invasive studies in healthy volunteers 
show that the slope of “linearized” mPAP/CO relationships 
ranges from 0.5 to 3.0 mmHg/L/min (Table 1).6,7 LAP increases 
during exercise with upstream transmission to mPAP.5,6,10-12 The 
increment in LAP during exercise also reduces pulmonary com-
pliance and thereby leads to an increase in transpulmonary pres-
sure gradient (mPAP minus LAP = TPG; Figure 3).13 However, 
LAP exceeds the upper limit of resting normal in healthy young 
adult subjects only at very high cardiac outputs, in the range 
of 20 L/min and greater.14 The pulmonary capillary wedge 
pressure (PCWP) to estimate LAP can increase to as high as 
25mmHg in exercising athletes.5 In fact, as reviewed by West, 
at very high levels of exercise elite athletes may develop pul-
monary edema and changes in the integrity and function of the 
blood-gas barrier that results in ‘exercise induced pulmonary 
hemorrhage’, a phenomenon common to race horses.15 In older 
subjects and particularly in heart failure patients, steep incre-
ments in LAP or PCWP are apparent during early exercise and 
contribute to mPAP/CO > 3.0mmHg/L/min. A disproportion-
ate increase in LAP or PCWP affects mPAP at lower levels of 
Figure 1. Limits of normal of mean pulmonary artery pressure 
(mPAP) as a function of cardiac output (CO) at exercise in healthy 
young adults, constructed from multi-point noninvasive (n=113) 
and invasive (n=24) measurements  reported in ref 7. All baseline 
resting measurements were within the limits of normal. No slope 
of linearized mPAP-CO relationships exceeded 3 mmHg/L/min. 
Slopes of mPAP-CO and derived distensibility calculations were 
identical in noninvasive and invasive studies. Stippled lines indi-
cate upper limits of mPAP at specified cardiac outputs.
Figure 2. Modeled mean pulmonary arterial pressure-cardiac 
output (mPAP-Q) relationships during dynamic exercise with 
progressively increased distensibility coefficients (α). The normal 
range of α values is 1-2%. Authorization for this adaptation has 
been o btained both from the owner of the copyright in the origi-
nal work and from the owner of copyright in the translation or 
adaptation. Adapted from reference 7, reprinted with permission 
of the American Thoracic Society.  Copyright © 2013 American 
Thoracic Society.
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exercise in older subjects5 and at very low levels of exercise in 
heart failure patients.5,16
Cardiac and pulmonary diseases may affect mPAP by 
increased PVR, increased LAP, and sometimes an increased 
CO. The limited data available point to a prominent effect of 
increased PVR as a cause of steeper mPAP/CO plots. A dis-
proportionate increase in mPAP, ie, more than predicted from 
the resting PVR equation, may also be due to pulmonary vaso-
constriction related to low mixed venous PO2, acidosis and 
sympathetic nervous system activation.5,17 Exercise-induced 
pulmonary vasoconstriction typically causes extrapolated 
pressure intercepts of mPAP/CO plots to be negative.16
When a sufficient number of mPAP-CO coordinates are 
generated, it becomes possible to identify patterns.11,12,16 Both 
linear and “take-off” patterns of mPAP-CO relationships have 
been observed in patients with left heart failure.11,16 A take-off 
pattern is explained by increased LAP or pulmonary vasocon-
striction. A “plateau pattern” may emerge, particularly when 
CO is replaced by O2 uptake (Vo2), based on the rationale that 
both variables are linearly related. An inability to increase 
CO at still-increasing Vo2 at the highest level of exercise may 
explain “plateauing” of the mPAP-Vo2 relationship in PAH.12
Recent studies have begun to clarify the clinical correlates 
of exercise-induced PH.11,12 Invasive and noninvasive stud-
ies have accumulated, showing that the slope of linearized 
mPAP-CO relationships should not exceed 3 mm Hg·L−1·min−1 
(Figure 1 and the Table6,9–12,16,18–32). This corresponds to the 
former definition of exercise-induced PH (mPAP >30 mm Hg) 
provided that CO remains <10 L/min or total pulmonary resis-
tance (mPAP/CO) at maximum exercise is <3 Wood units.
Although further work is needed to improve exercise test-
ing protocols for the diagnosis and follow-up of PH, several 
guiding principles and limitations deserve mention. Exercise 
should be dynamic, avoiding the increase in systemic vascular 
resistance and abrupt changes in intrathoracic pressure that 
occur with resistive exercise and might present with unpre-
dictable effects on the pulmonary circulation. Even with 
dynamic exercise, however, increased ventilation causes pul-
monary vascular pressures to vary greatly between inspiration 
and expiration, as reflected by respiratory swings of esopha-
geal pressures. Therefore, measuring pulmonary vascular 
pressures at end expiration, when esophageal pressures are 
positive (particularly in obstructive lung disease), may lead to 
a false diagnosis of exercise-induced PH. It is therefore pref-
erable to average the reading of pulmonary vascular pressures 
over the entire respiratory cycle. Postexercise measurements 
are thought to be unreliable because of the rapid return of 
pulmonary vascular pressures and flows to the baseline rest-
ing state. Even though workload or Vo2 and CO are linearly 
related, they should not be used as surrogates considering 
that a determinant of pulmonary vascular pressure is flow 
and the individual variability of workload or Vo2 versus CO 
relationships is high. Finally, recently developed noninvasive 
echocardiographic measurements of mPAP-CO relationships 
have been shown to closely approximate invasively measured 
mPAP-CO values,7,9,25 and may be feasible in highly dedicated 
centers with very experienced echocardiographers, but they 
require more validation to demonstrate clinical relevance.
Accepting a cutoff value of a slope of mPAP/CO plots >3 
mm Hg·L−1·min−1 or a total PVR >3 Wood units at maximum 
exercise does not clarify whether the abnormal pressure is attrib-
utable to pulmonary vasoconstriction, remodeling, or upstream 
transmission of a high LAP or PCWP. Thus, a better definition 
of the limits of normal of LAP at exercise is also needed. In the 
meantime, it can be safely assumed that the functional state of 
the pulmonary circulation is best described by >4- to 5-point 
(mPAP−LAP)/CO plots to calculate a slope (Figure 4).33
Heart Failure With Reduced 
LV Ejection Fraction
Heart failure with reduced LVEF (HFrEF) is commonly 
associated with the development of pulmonary hypertension 
(HFrEF-PH). HFrEF-PH purports a poor prognosis, particu-
larly when it is accompanied by RV dysfunction.34 Single rest-
ing right heart catheter or echocardiography measurements 
tend to vary with diurnal patterns, autonomic tone, and timing 
of medication exposures (ie, diuretics), which can confound 
conclusions about the degree of right ventricular-pulmonary 
vascular (RV-PV) dysfunction present in HFrEF.35 In contrast, 
exercise permits multiple measurements across varying load-
ing conditions to assess RV contractile reserve and the ability 
of the pulmonary vasculature to accommodate increased flow.36 
A recent study established that exercise in HFrEF elicits 
a steep increase in mPAP that is attributable to exaggerated 
increases in both TPG and PCWP.11 A steep linear increment 
in mPAP in response to exercise was independently associated 
with reduced exercise capacity (peak Vo2) and reduced survival 
in patients with HFrEF. Failure to augment mPAP throughout 
exercise, resulting in a plateau pattern of mPAP versus work 
during late exercise, was indicative of dynamic RV dysfunction 
Figure 3. Relationship between pulmonary capil-
lary wedge pressure (PCWP) and transpulmonary 
gradient (TPG) across the normal range of stroke 
volumes (SV) achieved during exercise.  DPG 
indicates diastolic pulmonary pressure gradient, 
which is the gradient between pulmonary arte-
rial diastolic pressure and PCWP. An increase in 
PCWP is normally associated with a proportion-
ately greater increase in mean pulmonary artery 
pressure (mPAP) than that of diastolic pulmonary 
artery pressure.  As PCWP increases, the DPG 
may decrease (A)  or remain unchanged (B). The 
different impact of increased PCWP on the TPG 
and the DPG is explained by the effects of SV and 
of PCWP on pulmonary arterial compliance.
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and portended a particularly poor prognosis.11 These findings 
complement previous studies showing that mPAP and PVR 
responses to exercise are more closely related to outcomes than 
resting hemodynamic measurements in HFrEF.11
Exercise echocardiography has also been used in the evalu-
ation of HFrEF-PH, although Doppler measures of right- and 
particularly left-side pressures can be challenging to ascertain 
during exercise and require further validation. Tumminello et al 
found that peak exercise pulmonary artery systolic pressure 
(PASP) in patients with HFrEF was related principally to mitral 
regurgitation and contractile reserve, whereas Maréchaux et al 
identified intraventricular dyssynchrony and impaired contrac-
tile reserve to be independent predictors of exercise-induced 
changes in PASP.38 Notably, very low tricuspid annular plane 
systolic excursion (<14 mm) predicted a more modest maxi-
mum increase in PASP during exercise, a finding that mirrors 
invasive data suggesting that marked impairment in RV perfor-
mance during exercise leads to a limited capacity to augment 
PASP and mPAP.11 The aforementioned echocardiography-
based studies focused on peak exercise PASP or peak exercise 
changes in PASP, which are attenuated if CO augmentation is 
modest during exercise. Therefore, it is preferable to interpret 
exercise mPAP augmentation patterns relative to increases in 
blood flow through the pulmonary circulation (mPAP/CO as 
described previously; see the Table).
Several mechanisms may account for the heightened 
mPAP/CO observed in HFrEF. Increased left-side pressures 
during exercise caused by HFrEF are to be expected, but exag-
gerated increases in TPG are also observed in HFrEF. This may 
be attributable to maximally recruited pulmonary vasculature at 
rest on account of elevated resting LV pressures, thus limiting 
passive recruitment and distension during exercise observed in 
Table.  Review of Exercise Stress Tests of the Pulmonary Circulation in Normal Subjects and in Patients With Chronic Obstructive 
Pulmonary Disease, Scleroderma, Left Heart Failure, and Pulmonary Arterial Hypertension.














Hickam et al18 8 23±7 Leg press 20±7 7.1±1.8 10.4±3.5 11±3 13±1 0.9
Lonsdorfer et al19 7 31±8 Cycle 276±50 5.4±1.5 20.0±3.3 14±2 27±6 0.9
Degre et al20 11 41±5 Cycle NA 5.0±0.9 13.3±1.7 11±4 23±5 1.4
Slonim et al21 5 22±2 Leg press 20±2 4.9±0.6 7.2±0.8 15±2 19±2 1.6
Wagner et al22 8 30±6 Cycle 180 6.9±2.0 20.5±2.5 13±3 30±6 1.2
Damato et al23 24 31±6 Treadmill 160±23 5.1±0.8 17.5±2.0 15±5 29±8 1.1
Reeves et al24 9 NA Cycle 240 6.7±1.2 24.7±3 15±2 29±8 0.8
Tolle et al12 16 46±15 Cycle 156±43 5.8±1.0 15.5±3.2 14±3 27±4 1.4
Argiento et al25 25 36±14 Cycle 170±51 4.7±1.0 18.0±4.2 14±3 30±7 1.4
Argiento et al9 113 37±13 Cycle 175±50 5.3±1.2 15±3 18±3.6 33±7 1.5
Kovacs et al6 16 >50 Cycle NA 6.2±1.5 13.1±1.7 15±4 32±7 2.5
COPD
Hickam et al18 5 51±10 Leg press 10 6.2±1.0 7.8±2.3 18±5 25±2.5 4.0
Saito et al26 14 67±7 Cycle 27 4.3±0.7 8.8±1.1 19±4 41±10 4.6






















  SSc-PH Saggar et al29 57 51±13 Cycle NA 5.2±1.4 9.4±3.1 18±4 35±8 4.5
Left heart failure
  HFrEF Lewis et al30 13 47±9 Cycle 83±10 3.2±0.2 4.8±0.3 28±4 36±4 5.0
  HFrEF Lewis et al11 60 60±12 Cycle 75±28 3.7±0.7 7.6±2.1 28±3 50±3 5.6
  HFrEF Mancini et al31
   Survivors 49 53±10 Cycle NA 4.0±1.1 7.7±2.1 28±11 46±12 4.9
   Nonsurvivors 16 52±8 4.1±0.8 7.1±2.3 31±10 55±8 8.0
  HFrEF Janicki et al16 42 NA Treadmill NA 3.7±1.3 5.9
  HFpEF Borlaug et al10 32 65±13 Cycle 47±19 5.2±1.1 9.1±1.9 19±4 43±7 6.1
PAH
Janicki et al16 9 NA Treadmill NA 3.4±0.7 8.9±2.7 43±16 81±16 6.1
Blumberg et al32 16 55±8 Cycle 25–50 3.7±1 5.8±2.4 45±8 70±13 11.9
CO indicates cardiac output; COPD, chronic obstructive lung disease; Ex, exercise; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with 
reduced left ventricular ejection fraction; mPAP, mean pulmonary arterial pressure; ΔmPAP/ΔCO, the slope of the pulmonary arterial pressure versus cardiac output 
during exercise; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; and SSc, systemic scleroderma.
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normal subjects. Elevations in PCWP also lower pulmonary 
artery compliance at a given PVR, leading to increased pul-
monary artery wave reflections and augmentation in PASP and 
thus mPAP.13,39 Subnormal Pao2 during exercise and an imbal-
ance between endothelium-derived vasoactive and vasocon-
strictive mediators may also contribute to increased pulmonary 
vascular tone in HFrEF.40 In support of the latter mechanism, 
inhibition of cyclic GMP hydrolysis with the phosphodiester-
ase 5 inhibitor sildenafil has been shown to improve exercise 
PVR and exercise capacity in HFrEF.30,36
A greater knowledge of compensatory responses of the 
RV–pulmonary vascular unit during exercise in patients with 
HFrEF may improve our understanding of its functional role 
in determining exercise capacity while aiding in earlier diag-
nosis of PH complicating HFrEF and informing targeted ther-
apeutic interventions.36
Heart Failure With Preserved 
LV Ejection Fraction
Heart failure with preserved LV ejection fraction (HFpEF) 
constitutes ≈40% of the heart failure population and is associ-
ated with a similar prognosis to HFrEF.41 HFpEF, like HFrEF, 
is associated with a steep increase in mPAP during exercise 
(Table). Echocardiography-based mechanistic studies indicate 
that exercise mPAP in HFpEF, unlike HFrEF, is most closely 
associated with degree of diastolic dysfunction.42 In both 
HFrEF and HFpEF, it is important not to overlook comorbid 
conditions that can contribute to PH such as chronic obstruc-
tive pulmonary disease (COPD), obstructive sleep apnea, val-
vular heart disease, or chronic thromboembolic PH.
Current guideline-based diagnostic criteria for HFpEF include 
objective evidence of elevated cardiac filling pressures based 
on cardiac catheterization, echocardiography, or natriuretic 
peptide assays.42,43 These criteria lead to potential underdiag-
nosis of HFpEF in symptomatic patients without hypervolemia. 
Borlaug et al reported invasive hemodynamic responses to exer-
cise in 55 euvolemic subjects with exertional dyspnea and nor-
mal resting hemodynamic measurements.10 A PCWP threshold 
of ≥25 mm Hg during supine cycle ergometry or weightlifting 
with the arms was used to diagnose HFpEF. HFpEF subjects 
experienced significantly greater exercise-induced increases in 
mPAP (ie, from 19±4 to 43±7 mm Hg; Table) than subjects with 
noncardiac dyspnea (ie, from 15±4 to 23±5 mm Hg) despite 
achieving lower peak COs. Exercise PASP is easily amenable 
to noninvasive measurement. In the same study, exercise PASP 
identified HFpEF with 96% sensitivity and 95% specificity 
using a cut point of 45 mm Hg. Exercise PASP outperformed 
resting PASP, natriuretic peptide levels, and echocardiographic 
indicators for diagnosing HFpEF.10
Similarly, Kitzman et al reported in 1991 that compensated 
outpatients with HFpEF had normal resting PCWP but marked 
increases in exercise PCWP, suggesting that HFpEF may ini-
tially manifest with only intermittent elevations in cardiac 
filling pressures.43 Both studies indicate that exercise hemody-
namic measurements are of incremental value for the diagnosis 
of HFpEF and may provide a window into earlier diagnosis 
of the condition. However, at present, there is no consensus 
on the appropriate partition value to define an abnormal exer-
cise PCWP or LV end-diastolic pressure, with suggested cut-
off values ranging from 15 to 25 mm Hg. Furthermore, before 
labeling elevations in exercise hemodynamic measurements as 
early forms of HFpEF, more information is needed on the natu-
ral history of patients with exercise elevations in mPAP and 
PCWP to determine the rate at which they go on to develop 
adverse outcomes known to be associated with overt HFpEF.
In addition to assisting with the diagnosis of HFpEF in 
the setting of normal resting hemodynamic measurements, 
exercise may be of particular value is assessing the entity 
of PH out of proportion to LV dysfunction, alternatively 
called  PH–LV dysfunction or mixed PH.45 In mixed PH, the 
partitioning of relative contributions of PCWP and TPG to 
exercise mPAP may help to further phenotype patients with 
dyspnea and to inform targeted interventions directed at either 
the LV or the pulmonary vasculature. Indeed, a recent trial 
of phosphodiesterase 5 inhibition in HFpEF subjects with a 
high burden of resting precapillary PH and RV dysfunction 
showed marked improvement in mPAP, PVR, and quality 
of life with sildenafil treatment.45 In contrast, in a broader 
HFpEF population in whom neither PH nor RV dysfunction 
was mandated by inclusion criteria, sildenafil did not improve 
exercise capacity.46 Whether exercise hemodynamic responses 
can identify HFpEF subjects with earlier forms of abnormal 
RV–pulmonary vascular reserve capacity who will benefit 
from RV–pulmonary vascular–directed interventions is being 
actively investigated.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare disease 
associated with remodeling of the small pulmonary arteries, 
Figure 4. Linear mean pulmonary arterial pressure (mPAP)-flow 
relationships based on averages of serial measurements of mean 
PAP and cardiac output during incremental exercise. Normal young 
adults (□ ), patients with scleroderma with PAP in the lower normal 
range (◊) and borderline-PH range (♦), and patients with resting 
PAH (•) demonstrate approximately linear pressure-flow responses 
during exercise. Despite similar resting mPAP and CO in normals 
and the two scleroderma subgroups, exercise elicits a steeper 
increment in PAP vs. CO in scleroderma borderline-PH group (♦). 
The mPAP-CO slope of > 3.0 (dashed reference line) represents 
an abnormal pulmonary vascular response to exercise and may be 
indicative of early pulmonary vasculopathy. Adapted from reference 
33. Authorization for this adaptation has been obtained both from 
the owner of the copyright in the original work and from the owner 
of the copyright in the translation or adaptation. Reprinted with per-
mission of Advances in Pulmonary Hypertension. Copyright © 2013 
Advances in Pulmonary Hypertension.
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leading to an increase in PVR, adaptive right heart hyper-
trophy, and right heart failure.1,2 Numerous pathogenic fac-
tors and diseases affecting the pulmonary vascular bed have 
been identified that result in a similar clinical phenotype with 
impaired exercise capacity, quality of life, and prognosis. The 
diagnosis of PAH requires confirmation by direct assessment 
of invasive hemodynamic parameters at rest.1,2
As reviewed by Bossone et al, there have been a limited 
number of studies that have evaluated invasive hemodynam-
ics during exercise in PAH.5 Whereas healthy subjects can 
achieve a more than 10-fold increase in VO2 during exercise 
due to a complex cardiovascular, ventilatory and peripheral 
response, in PAH patients peak VO2 is significantly reduced. 
Patients with PAH are mainly limited by a reduced CO at rest 
and during exercise and have steep mPAP-CO relationships.16 
RV dysfunction is the most important factor contributing to 
functional impairment and mortality. 
Despite the lack of adequate standards, there is increas-
ing enthusiasm for performing noninvasive assessment of 
exercise hemodynamics to screen for PAH and to assess 
prognosis. As reviewed by Bossone and Naeije,4 the clini-
cal phenotype of normal pulmonary arterial pressure at rest 
and high response during exercise has been evaluated with 
recumbent exercise echo Doppler studies in subjects at risk 
for PAH in 10 studies involving 824 subjects (427 with con-
nective tissue disease, 54 with congenital heart disease, and 
343 relatives of idiopathic PAH cases).5 Although the mea-
surement of PASP during symptom-limited exercise or at 
given workloads is of interest as a screening tool for PAH, 
it is not adequate for determining whether the exaggerated 
exercise-induced increase in PASP in persons with dyspnea 
or fatigue is attributable to a precapillary (PAH) or postcapil-
lary (pulmonary venous hypertension) source. It may be help-
ful for selecting high-risk patients who would benefit from 
direct measurement of invasive hemodynamics at rest and 
with exercise such as those with a family history of PAH or 
connective tissue diseases (discussed below).
Grünig et al demonstrated the use of recumbent exercise 
echo Doppler for identifying asymptomatic family members 
of idiopathic PAH patients carrying a predisposing mutation 
in the bone morphogenetic protein receptor II gene in 2 fami-
lies47 and subsequently led a multicenter study in 291 relatives 
of 109 PAH patients and 191 age-matched control subjects 
from 6 centers in European countries.48 During exercise (mean 
maximal workload of 148 W in control subjects and 124 W in 
relatives), 10% of control subjects but 31.6% of the relatives 
(P<0.0001) exceeded the 90th percentile of mean maximal tri-
cuspid regurgitation velocity of >3.08 m/s (corresponding to 
PASP of >43 mm Hg) seen in control subjects.
Tolle et al conducted a landmark study demonstrating that 
the pattern and severity of the invasive hemodynamic response 
to cycle ergometry exercise (symptom limited with peak heart 
rate ≥80% of predicted or respiratory exchange ratio of ≥1) in 
exercise-induced PAH are intermediate between those of the 
normal subject and those of the patient with resting PAH and 
provide support for the hypothesis that exercise-induced PAH is 
a mild yet symptomatic phase of the disease.8 Cardiopulmonary 
exercise testing was used to diagnose the cause of dyspnea 
or fatigue in 255 patients; of these patients, the concluding 
diagnosis was PAH in 93 and 16 were considered normal. Of 
the PAH group, 78 had exercise-induced PAH and 15 had evi-
dence of PAH at rest (mPAP ≥25 mm Hg). The mean (2 SD) 
mPAP with exercise was 27.4 mm Hg (7.4 mm Hg) in the nor-
mal group, 36.6 mm Hg (11.4 mm Hg) in the exercise-induced 
group, and 48.4 mm Hg (22.2 mm Hg) in those with resting 
PAH, whereas the PCWP and mRAP did not differ between 
groups. Consistent with findings in HFrEF, a plateau pattern in 
PAP versus Vo2 (or CO) in exercise-induced PAH patients was 
associated with worse functional capacity.12 Interestingly, rest-
ing mPAP, including those in an “indeterminate” range of 21 
to 25 mm Hg, did not reliably predict exercise-induced PAH.
Exercise hemodynamics in idiopathic PAH on PAH-specific 
treatment correlates much better with improved exercise tol-
erance than resting hemodynamics. Extending earlier obser-
vations by their group, in 2008, Provencher et al evaluated 
42 patients with idiopathic PAH at baseline and after PAH-
specific treatments for an average of 5 months.49 With a 43-m 
improvement in 6-minute walk distance, on multivariate anal-
ysis, improvement was related to changes in cycle exercise (40 
W) hemodynamics; specifically, the peak cardiac index was 
achieved at a lower mPAP, consistent with exercise vasodila-
tion. Whether a change in pressure-flow relationship response 
(∆mPAP/∆CO; Figures 1 and 2) at a given workload, target 
heart rate, or percent of aerobic capacity will improve risk 
stratification and treatment decisions is an important area of 
future research in PAH.
Exercise Hemodynamics in Scleroderma
Patients with scleroderma are considered an at-risk group 
for developing PH, which when present is the major cause of 
death.1,2 They may have latent or asymptomatic PAH, associ-
ated with hypoxemia and lung disease, as well as LV dia-
stolic dysfunction or pulmonary venous hypertension from 
hypertension or scleroderma cardiomyopathy.50,51 Although 
the definition of PH requires an mPAP ≥ 25 mm Hg, there 
is evidence that scleroderma patients with a baseline “bor-
derline” resting mPAP of 21 to 24 mm Hg and with exagger-
ated PAP response to exercise are at higher risk of developing 
progressive pulmonary vascular disease.52,53 This suggests 
that the hemodynamic response to exercise in scleroderma, 
as assessed by echo Doppler and heart catheterization, may 
detect those who are likely to develop rapidly progressive 
PAH in a preclinical phase that may respond to therapy. The 
importance of such efforts is supported by several studies. RV 
diastolic dysfunction has been found in patients with sclero-
derma and normal resting but abnormal exercise PH (latent 
PH) scleroderma.50 Kovacs and colleagues52 reassessed exer-
cise invasive hemodynamics (50 W and maximum exercise) 
in 10 borderline PAH patients with scleroderma after a 1-year 
observation period; a progression was noted in pertinent 
hemodynamic variables (mPA and PVR). Furthermore, in the 
UK PH registry, one fifth of scleroderma patients with exer-
cise PH developed resting PAH after ≈2.3 years.53
The frequency, spectrum, and significance of a hyperten-
sive PAP response to exercise in scleroderma are currently 
uncertain. The PAP response may reflect a normal variant (eg, 
related to age) without clinical significance or a manifestation 
of abnormal pulmonary arterial vasodilator reserve and may 
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be composed of precapillary or postcapillary pathological rises 
in pressure. Saggar et al54 assessed the invasive hemodynamic 
response to recumbent submaximal cycle exercise in 57 patients 
with dyspnea and clinical scleroderma who had normal resting 
hemodynamics but decreased Dlco or a FVC:Dlco percent pre-
dicted ratio >1.4. Those with an LV ejection fraction <50% or 
more than mild LV diastolic dysfunction were excluded. They 
found 4 distinct groups: normal in 26%, exercise pulmonary 
venous hypertension in 21% (mPA >30 mm Hg, PCWP >18 
mm Hg, and TPG <15 mm Hg), exercise out-of-proportion PH 
in 16% (mPA >30 mm Hg, PCWP >18 mm Hg, and TPG ≥15 
mm Hg), and exercise PAH in 37% (mPA >30 mm Hg, PCWP 
<18 mm Hg, and TPG >15 mm Hg). A baseline mPAP <14 
mm Hg was not associated with exercise PH or exercise out-
of-proportion PH, whereas a resting mPAP >20 mm Hg has a 
90% positive predictive value for exercise PH, exercise out-
of-proportion PH, or pulmonary venous hypertension, and a 
concurrent PVR ≥ 2 Wood units had a positive predictive value 
of 100%. For those with an mPAP of 14 to 20 mm Hg, a low 
normal PVR had a negative predictive value of 100%, and a 
PVR ≥ 2 Wood units had a positive predictive value of 89% for 
predicting exercise PH and exercise out-of-proportion PH. In a 
similar study of 54 patients with scleroderma at risk for PH, of 
the 17 patients with an RV systolic pressure <35 mm Hg at rest 
and at least a 20-mm Hg increase in RV systolic pressure dur-
ing stress echo Doppler, during the heart catheterization with 
exercise conducted by arm exercise with weights, 1 patient had 
no PH, 3 patients had evidence of LV diastolic dysfunction, 
and 13 patients had exercise-induced PAH.51
Finally, a recent uncontrolled, open-label study suggested 
that chronic oral administration of ambrisentan may be asso-
ciated with significant improvement in exercise cardiopulmo-
nary hemodynamics and exercise capacity (6MW) in patients 
with SSc-spectrum and normal resting PAP but exercise 
PH.29 These improvements included a significant decrease in 
exercise PVR, total pulmonary resistance, and mPAP, and an 
increase in CO and SV.29 The clinical significance of these 
observations needs to be validated by a larger placebo con-
trolled randomized study.
Further work defining normal versus abnormal ΔPAP/ΔCO 
specifically for patients with scleroderma, with and without 
interstitial lung disease, needs to be conducted. Nonetheless, 
an exercise evaluation of scleroderma-PAH patients may 
allow earlier diagnosis, earlier initiation of therapy, and per-
haps a more favorable outcome.
Valvular Heart Disease
PH at rest and exaggerated during recumbent exercise testing 
is associated with an adverse outcome in patients with aortic 
and mitral valvular disease.55 The presence of PH at rest or 
during exercise should therefore be included in perioperative 
risk assessment of mitral and aortic valve replacement.56,57 In 
older patients with severe mitral valve stenosis and PH, the 
perioperative mortality increases to 20%; therefore, the indica-
tion of valve surgery has to be proven carefully.56 Preoperative 
PH was also an independent risk factor for long-term survival 
in patients with aortic valve replacement.57,58
Patients with valvular disease and normal or mildly ele-
vated PASP at rest may develop severe PH during exercise, 
which may be unrelated to the resting pressure.37,59 The level 
of increase in PASP depends on the ability to successfully 
recruit the pulmonary vasculature to accommodate increased 
blood flow with exercise, the contribution (or proportion) of 
the reduction in cross-sectional area of the pulmonary circula-
tion, the reduction in pulmonary vascular compliance, and the 
increase in LAP, each of which may be abnormal at rest.37
Mitral Valve Disease
Although the number of studies of exercise in mitral valve 
disease is limited, they consistently demonstrate that exercise-
induced PH is associated with a poor outcome. Functional 
mitral regurgitation secondary to chronic LV dysfunction is 
associated with dynamic changes in PASP (as estimated by the 
transtricuspid pressure gradient) during exercise, and there is 
a correlation between the rise in PASP during exercise and the 
increase in mitral regurgitation.37,59,60 The increase in PASP is 
more pronounced in patients with exercise-limiting dyspnea 
and in those hospitalized for acute pulmonary edema,37 and 
the acute increase in PASP during exercise independently pre-
dicts cardiac death and heart failure admission.60 The optimal 
cut point for predicting an increase in cardiac events was a 
21-mm Hg increase in PASP. Considering the adverse prognos-
tic implications of exercise-induced changes in mitral regurgita-
tion, for patients with moderate functional mitral regurgitation 
in whom surgical coronary revascularization is planned, an 
exaggerated increase in mitral regurgitation, PASP, and dys-
pnea during exercise echocardiography may aid in the decision 
of whether to include mitral valve intervention.61 The PASP 
increases markedly during exercise in a large proportion (46%) 
of patients with asymptomatic degenerative mitral regurgitation 
(prolapse or flail), and the change in PASP correlates with the 
change in effective regurgitant orifice and regurgitant volume.62 
In this cohort, development of PH during exercise is associ-
ated with a 3-fold increased risk of developing symptoms at 
3 years, whereas resting PH was not an independent predictor 
of outcome.62 The best cutoff value of PASP during exercise 
for predicting events was 56 mm Hg. Although there are no 
prospective prognostic data, a similar threshold of PASP with 
exercise (>60 mm Hg) has been recommended by the American 
College of Cardiology/American Heart Association guidelines 
for mitral valve intervention in patients with asymptomatic 
moderate to severe mitral stenosis (Class IIa indication; Level 
of Evidence, C), a recommendation not supported in the more 
recent European Society of Cardiology guidelines.61
Aortic Valve Disease
A resting PASP >50 mm Hg is present in ≈6% of asymptom-
atic patients with severe aortic stenosis.63 This suggests that the 
impact of severe aortic stenosis on LV diastolic function and 
left atrial geometry and function may generally be counterbal-
anced effectively by increasing left atrial compliance and pul-
monary vasodilator reserve. Using the definition of exercise PH 
as a PASP >60 mm Hg, Lancellotti et al63 recently reported that 
exercise PH is frequent (55% of the cohort) in the elderly with 
asymptomatic severe aortic stenosis (aortic valve area <0.6 
cm2/m2) and preserved LV ejection fraction. The rise in PASP 
was determined predominantly by the degrees of LV relaxation 
and left atrial compliance. For a given increase in LV filling 
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pressure, patients with smaller changes in left atrial dimen-
sions (ie, exhausted left atrial compliance reserve) during exer-
cise displayed a higher increase in PASP during exercise; this 
relationship was even stronger as recruitable left atrial function 
diminished, consistent with reduced atrial emptying associated 
with reduced left atrial function. Most important, exercise PH 
in asymptomatic severe AS was associated with an alarming 
rate of cardiac death (12%) and reduced overall 3-year car-
diac event-free survival (22±7% versus 55±9%; P=0.014), and 
exercise PH was an independent predictor of cardiac events.63
Chronic Obstructive Lung Disease
The prevalence of PH (defined as echo Doppler PASP >35 
mm Hg or mPAP >20 mm Hg on right heart catheterization) 
ranges between 30% and 70% in COPD (group 3 PH).64 PH 
in COPD is highly correlated with a decrease in functional 
capacity and mortality. A close relationship exists between the 
severity of hypoxemia and mPAP and PVR in COPD, suggest-
ing that alveolar hypoxia causes constriction of the resistance 
vessels and over time induces pulmonary vascular remodel-
ing. However, severe PH (mPA >35-40 mm Hg) occurs in 
<5% of persons with COPD and typically is associated with 
less severe obstruction, more hypoxemia and hypocapnia, and 
lower Dlco.64 The latter is characterized as disproportionate 
or out-of proportion PH. In a series of COPD patients with 
an mPA ≥40 mm Hg, 60% were related to other associated 
conditions, including appetite suppressants, collagen vascular 
disease, portal hypertension, LV disease, chronic thromboem-
bolic PH, and obstructive sleep apnea.65
In the middle-aged and elderly, a greater extent of emphy-
sema on computed tomography scanning and more severe air-
flow obstruction are linearly related to impaired LV filling, 
reduced stroke volume, and lower CO without changes in the 
ejection fraction.66 In addition, a low forced expiratory vol-
ume in the first second of expiration (FEV1) and obstructive 
airway disease are associated with a 2- to 3-fold long-term 
(15-year) risk of incident heart failure in middle-aged men and 
women.67 Thus, in COPD, it is highly likely LV diastolic dys-
function is a contributor to reduced exercise capacity and PH 
at rest and/or during exercise.
Patients with COPD whose exercising mPA is >30 mm Hg 
are more prone to develop resting PH (mean, 6 years) compared 
with patients whose exercising mPA is within normal limits.68 
An exercise study was conducted in 98 COPD patients with rest-
ing PH (27% with ≥25 mm Hg) and without resting PH (73% 
with <25 mm Hg) and no LV dysfunction or comorbidities. The 
prevalence of PH was 5%, 27%, and 53% in Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) stages II, III, and IV, 
respectively.28 Exercise resulted in an abnormal hemodynamic 
response (defined as ΔmPAP/ΔCO >3 mm Hg·L−1·min−1) in the 
resting PH group, ΔmPAP/ΔCO 7.17±4.88 mm Hg·L−1·min−1, 
as well as in the no PH group, ΔmPAP/ΔCO 4.55±3.33 
mm Hg·L−1·min−1. Similar results were obtained in both groups 
for ΔmPAP/Δwatts. These results support that the exercise-
induced rise in mPAP should be interpreted relative to the 
increase in CO or possibly watts, rather than relying on single 
absolute value of mPAP. However, caution is needed in the eval-
uation of mPAP-CO slope in COPD because intrathoracic pres-
sure is more positive than negative during exercise in COPD.
Conclusions and Future Directions
There is growing evidence that measurement of PAP during 
dynamic exercise provides valuable incremental information 
to resting hemodynamic measurements alone. Recent studies 
have established that an exaggerated increment in PAP dur-
ing exercise is closely associated with impaired functional 
capacity in HF,11 PAH,12,49 exercise-induced PH,12 and valvu-
lar heart disease.37,62 Additional recent studies have shown that 
exercise PAP responses potently predict adverse outcomes in 
HF11 and valvular heart disease55,60,62,63 and also predict future 
PH progression in patients with COPD.68 However, studies to 
date have been conducted in relatively small cohorts, using 
heterogenous exercise protocols, measurement methods, and 
definitions of abnormal hemodynamic responses to exercise.
From the studies summarized here, we conclude that ideally 
multipoint assessments of mPAP relative to CO should be per-
formed during dynamic exercise, with an mPAP-CO slope >3 
mm Hg·L−1·min−1 signaling an abnormal pulmonary vascular 
response to exercise. Determination of LAP or PCWP during 
exercise is also important to ascertain precapillary and post-
capillary contributions to mPAP during exercise, but optimal 
cut points for abnormal exercise LAP or PCWP have not been 
defined.10 Future investigations are needed to further validate 
noninvasive methods for the evaluation of the RV and pul-
monary vasculature during exercise and to further define the 
functional and prognostic significance of PAP-Q responses 
to exercise in various cardiopulmonary diseases. Finally, 
understanding the natural history of abnormal exercise P-Q 
responses and their modifiability with interventions (ie, oxy-
gen therapy, exercise training, pulmonary vasodilators) will 
help determine whether exercise hemodynamic measurements 
can be used to diagnose early forms of PH and to inform the 
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